Radiation for human papillomavirus

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Memorial Sloan Kettering Cancer Center at Suffolk-Commack (Limited Protocol Activities), Commack, NY
human papillomavirus+7 More
Radiation - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to find out if lower doses of radiation may help reduce the side effects of radiation therapy in combination with standard-of-care chemotherapy in people with HPV-positive throat cancer. The chemotherapy drugs used in this study include cisplatin, carboplatin, and 5-fluorouracil (5- FU).

Eligible Conditions

  • HPV
  • human papillomavirus
  • Oropharyngeal Carcinoma
  • Oropharyngeal Cancers
  • Throat Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for human papillomavirus

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 2 years

2 years
Number of participants with any locoregional recurrences

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for human papillomavirus

Trial Design

1 Treatment Group

Participants with HPV-Positive Throat Cancer
1 of 1
Experimental Treatment

71 Total Participants · 1 Treatment Group

Primary Treatment: Radiation · No Placebo Group · Phase 2

Participants with HPV-Positive Throat CancerExperimental Group · 5 Interventions: Carboplatin, 18 F-FMISO PET/CT, Radiation, Cisplatin, 5-fluorouracil · Intervention Types: Drug, DiagnosticTest, Radiation, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
2014
Completed Phase 3
~6570
Radiation
2005
Completed Phase 3
~990
Cisplatin
2013
Completed Phase 3
~3340
5-fluorouracil
2005
Completed Phase 4
~7820

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
Closest Location: Memorial Sloan Kettering Cancer Center at Suffolk-Commack (Limited Protocol Activities) · Commack, NY
Photo of new york 1Photo of new york 2Photo of new york 3
N/AFirst Recorded Clinical Trial
0 TrialsResearching human papillomavirus
0 CompletedClinical Trials

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,806 Previous Clinical Trials
589,257 Total Patients Enrolled
Nancy Lee, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
10 Previous Clinical Trials
1,288 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Subjects must have clinically or radiographically evident measurable gross disease at either the primary tumor site or nodal stations.
A primary squamous cell carcinoma of the neck of unknown primary is allowed with excision biopsy of a lymph node (or core biopsy) or consent from the PI or co-PI.
You have a CT or PET/CT scan of the neck with and without contrast.
You have a performance status of 0-2 or KPS ≥ 50.
You have a white blood count (WBC) of 2,000 or more per microliter (μl).
The absolute neutrophil count (ANC) is ≥ 1,000 cells/mm3.
You have a platelet count of at least 100,000 cells/mm3.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.